|
|
|
|
| UBD243d | 膀胱癌及癌旁组织组合芯片，附病理分级、TNM和临床分期，12例/24点，替代UBD243c | | | 点 数 | 24 | 例 数 | 12 | | 行 数 | 4 | 列 数 | 6 | | 点直径(mm) | 1.5 | 厚度(µm) | 5.0 | | 组织阵列类型 | 石蜡包埋 | 种 属 | 人类 | | QA/QC | | | Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | | Notes | 1.Please keep the slides at 4 ℃ after receiving, and make experiment within 3 months will be better. 2.Bake the slides for 30 minutes at 60℃ before the experiment; 3.Please choose a gentle repair method to avoid tissue detachment. |
|
|
| |
|
Legend:
|
|
AT Malignant (I) Malignant (II) Malignant (IIB) Malignant (IV) NAT |
|
|
|
| |
| Pos | No | Age | Sex | Organ_Anatomic_Site | Pathology_diagnosis | Grade | TNM | Stage | Type |
| A1 | 1 | 56 | M | Bladder | Urothelial carcinoma | 2 | T2N0M0 | II | Malignant |
| A2 | 2 | 56 | M | Bladder | Urothelial carcinoma | 2 | T2N0M0 | II | Malignant |
| A3 | 3 | 47 | M | Bladder | Urothelial carcinoma | 2 | T2aN0M0 | II | Malignant |
| A4 | 4 | 47 | M | Bladder | Urothelial carcinoma | 2 | T2aN0M0 | II | Malignant |
| A5 | 5 | 72 | M | Bladder | Urothelial carcinoma | - | T2N0M0 | IIB | Malignant |
| A6 | 6 | 72 | M | Bladder | Urothelial carcinoma | - | T2N0M0 | IIB | Malignant |
| B1 | 7 | 53 | M | Bladder | Urothelial carcinoma | 1--2 | T2aN0M0 | II | Malignant |
| B2 | 8 | 53 | M | Bladder | Urothelial carcinoma | 1--2 | T2aN0M0 | II | Malignant |
| B3 | 9 | 82 | M | Bladder | Urothelial carcinoma | 2 | T1N0M0 | I | Malignant |
| B4 | 10 | 82 | M | Bladder | Urothelial carcinoma | 2 | T1N0M0 | I | Malignant |
| B5 | 11 | 43 | F | Bladder | Urothelial carcinoma | - | T2N0M0 | II | Malignant |
| B6 | 12 | 43 | F | Bladder | Urothelial carcinoma | - | T2N0M0 | II | Malignant |
| C1 | 13 | 44 | F | Bladder | Urothelial carcinoma | 2 | T2aN0M0 | II | Malignant |
| C2 | 14 | 44 | F | Bladder | Urothelial carcinoma | 2 | T2aN0M0 | II | Malignant |
| C3 | 15 | 47 | F | Bladder | Urothelial carcinoma | - | T2bN0M0 | II | Malignant |
| C4 | 16 | 47 | F | Bladder | Urothelial carcinoma | - | T2bN0M0 | II | Malignant |
| C5 | 17 | 57 | M | Bladder | Adenocarcinoma | 2 | T1N0M0 | II | Malignant |
| C6 | 18 | 57 | M | Bladder | Adenocarcinoma | 2 | T1N0M0 | II | Malignant |
| D1 | 19 | 58 | M | Bladder | Adenocarcinoma | 2 | T3N1M0 | IV | Malignant |
| D2 | 20 | 58 | M | Bladder | Adenocarcinoma | 2 | T3N1M0 | IV | Malignant |
| D3 | 21 | 45 | M | Bladder | Cancer adjacent bladder tissue | - | - | - | AT |
| D4 | 22 | 45 | M | Bladder | Cancer adjacent bladder tissue | - | - | - | AT |
| D5 | 23 | 49 | F | Bladder | Adjacent normal bladder tissue | - | - | - | NAT |
| D6 | 24 | 49 | F | Bladder | Adjacent normal bladder tissue | - | - | - | NAT | | Tissue Marker |
|
|
